Regeneron's core Eylea patent position is strengthened after the court dismissed several high-impact claims from Amgen. However, the laches counterclaim survives, meaning a path to unenforceability of the '099 patent remains open. Monitor developments on laches and whether Amgen seeks leave to amend its antitrust claims on the 2024 Litigation Patents. Next major catalyst is likely the claim construction or summary judgment rulings on the '099 patent's validity.
Price Chart
Executive Summary
Regeneron won a significant motion in its patent infringement litigation against Amgen, with the court striking Amgen's inequitable conduct, patent misuse, and unclean hands defenses and dismissing related counterclaims with prejudice, and dismissing antitrust/UCL counterclaims with prejudice as to the '099 patent. The laches defense and counterclaim survive, preserving some uncertainty, but the ruling substantially narrows the case and removes high-risk claims that could have threatened enforceability of Regeneron's Eylea patents.
Court Ruling Details
Key Facts
- Court struck Amgen's inequitable conduct defense/counterclaim with prejudice (Thirteenth Additional Defense and Fourth Counterclaim)
- Court struck Amgen's patent misuse defense/counterclaim with prejudice (Fourteenth Additional Defense and Fifth Counterclaim)
- Court struck Amgen's unclean hands defense with prejudice (Fourth Additional Defense)
- Court dismissed Amgen's antitrust counterclaims with prejudice as to the '099 patent and without prejudice as to the 2024 Litigation Patents
- Court dismissed Amgen's UCL counterclaim with prejudice as to the '099 patent and without prejudice as to the 2024 Litigation Patents
- Court denied Regeneron's motion to dismiss Amgen's laches defense and counterclaim, allowing that claim to proceed
- The ruling does not address the validity or infringement of the '099 patent itself; no damages were awarded
Financial Impact
No damages awarded. The ruling removes the risk of the '099 patent being found unenforceable due to inequitable conduct, patent misuse, or unclean hands, and eliminates antitrust exposure tied to the '099 patent. The laches claim survival keeps some risk of unenforceability alive.
Risk Factors
- The laches defense and counterclaim survive, potentially creating a path to unenforceability of the '099 patent
- Antitrust counterclaims related to the 2024 Litigation Patents were dismissed without prejudice and could be repleaded
- The underlying patent infringement case continues, and Regeneron lost its preliminary injunction bid earlier
- Post-trial or appeal could reverse favorable rulings on inequitable conduct or patent misuse
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 court opinion from CourtListener.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-d2d7cbf308-REGN |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 1d ago | ANALYST-UPGRADE | — | awaiting T+20 | — | — |
Sep 3, 2026 29d ago | Insider Cluster | $843.47 $735.20 | ▼ −12.84% | ▼ −11.65% | $735.20 (−12.84%) |
Aug 24, 2026 5w ago | Court Ruling | $828.50 $803.90 | ▼ −2.97% | ▼ −4.28% | $735.20 (−11.26%) |
Aug 20, 2026 6w ago | Press Release | $826.64 $784.85 | ▼ −5.06% | ▼ −5.06% | $735.20 (−11.06%) |
Aug 12, 2026 7w ago | Insider Cluster | $797.99 $793.26 | ▼ −0.59% | ▲ +1.30% | $735.20 (−7.87%) |
Aug 11, 2026 7w ago | Court Ruling | $797.00 $807.65 | ▲ +1.34% | ▲ +2.40% | $735.20 (−7.75%) |
Jul 30, 2026 9w ago | 8-K | $738.34 $807.71 | ▲ +9.40% | ▲ +5.43% | $735.20 (−0.43%) |
Jul 30, 2026 9w ago | Press Release | $738.34 $807.71 | ▲ +9.40% | ▲ +5.43% | $735.20 (−0.43%) |
Jul 27, 2026 9w ago | Press Release | $695.18 $833.56 | ▼ −19.91% | ▼ −16.52% | $735.20 (−5.76%) |
Jul 17, 2026 11w ago | Press Release | $676.69 $800.70 | ▲ +18.33% | ▲ +13.88% | $735.20 (+8.65%) |
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more — parsed and scored by AI.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access